Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicola Battelli

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Immunology Letters|November 28, 2020
Gut microbiota, immunity and painMatteo Santoni, Francesca Miccini, Nicola Battelli
Biochimica Et Biophysica Acta. Reviews on Cancer|May 1, 2021
Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophagesMatteo Santoni, Francesco Massari, Rodolfo Montironi, et al.
Frontiers in Oncology|September 25, 2018
Urinary Markers in Bladder Cancer: An UpdateGiorgio Santoni, Maria B Morelli, Consuelo Amantini, et al.
Tumori|October 13, 2011
Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensityNicola Battelli, Alessandro Bittoni, Alessandra Pagliacci, et al.
Expert Opinion on Pharmacotherapy|August 18, 2021
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinomaAndrea Marchetti, Matteo Rosellini, Alessandro Rizzo, et al.
Tumori|May 20, 2022
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysisMatteo Santoni, Francesco Massari, Alessandro Rizzo, et al.
Current Oncology (Toronto, Ont.)|April 25, 2025
New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2-Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and IIINicola Battelli, Carmela Mocerino, Michele Montedoro, et al.
Anticancer Research|June 11, 2013
Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practiceMirco Pistelli, Alessandra Pagliacci, Nicola Battelli, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 1, 2021
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysisMatteo Santoni, Alessandro Rizzo, Veronica Mollica, et al.
Diagnostics (Basel, Switzerland)|December 19, 2020
Exploring the Spectrum of Kidney CiliopathiesMatteo Santoni, Francesco Piva, Alessia Cimadamore, et al.
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Immunology Letters|November 28, 2020
Gut microbiota, immunity and painMatteo Santoni, Francesca Miccini, Nicola Battelli
Biochimica Et Biophysica Acta. Reviews on Cancer|May 1, 2021
Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophagesMatteo Santoni, Francesco Massari, Rodolfo Montironi, et al.
Frontiers in Oncology|September 25, 2018
Urinary Markers in Bladder Cancer: An UpdateGiorgio Santoni, Maria B Morelli, Consuelo Amantini, et al.
Tumori|October 13, 2011
Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensityNicola Battelli, Alessandro Bittoni, Alessandra Pagliacci, et al.
Expert Opinion on Pharmacotherapy|August 18, 2021
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinomaAndrea Marchetti, Matteo Rosellini, Alessandro Rizzo, et al.
Tumori|May 20, 2022
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysisMatteo Santoni, Francesco Massari, Alessandro Rizzo, et al.
Current Oncology (Toronto, Ont.)|April 25, 2025
New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2-Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and IIINicola Battelli, Carmela Mocerino, Michele Montedoro, et al.
Anticancer Research|June 11, 2013
Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practiceMirco Pistelli, Alessandra Pagliacci, Nicola Battelli, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 1, 2021
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysisMatteo Santoni, Alessandro Rizzo, Veronica Mollica, et al.
Diagnostics (Basel, Switzerland)|December 19, 2020
Exploring the Spectrum of Kidney CiliopathiesMatteo Santoni, Francesco Piva, Alessia Cimadamore, et al.
Pageof 9